Urinary trypsin inhibitor reduces LPS-induced hypotension by suppressing tumor necrosis factor-α production through inhibition of Egr-1 expression

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 3 57-3, 2005, Pages

  Molor Erdene, Perenlei ^a   Okajima, Kenji ^a   Isobe, Hirotaka ^a   Uchiba, Mitsuhiro ^a   Harada, Naoaki ^a   Okabe, Hiroaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Early growth response factor 1; Inducible nitric oxide synthase; Lipopolysaccharide; Septic shock

Indexed keywords

AMINOGUANIDINE; EARLY GROWTH RESPONSE FACTOR 1; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRATE; NITRITE; PROTEIN C FOS; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPOTENSION; IN VITRO STUDY; INFLAMMATION; LUNG PARENCHYMA; MALE; MEAN ARTERIAL PRESSURE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; RAT; SEPTIC SHOCK; WESTERN BLOTTING;

ANIMALS; DRUG INTERACTIONS; GLYCOPROTEINS; HUMANS; HYPOTENSION; INSULIN-LIKE GROWTH FACTOR I; LIPOPOLYSACCHARIDES; LUNG; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCYTES; NF-KAPPA B; NITRATES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PHOSPHORYLATION; RATS; RATS, WISTAR; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13944266755     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00885.2004     Document Type: Article

References (31)

1. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, and Matsumoto A. Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor α production of monocytes. Shock 15: 101-105, 2001.
2. Barron RL. Pathophysiology of septic shock and implications for therapy. Clin Pharm 12: 829-845, 1993.
3. Fries E and Blom AM. Bikunin-not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 32: 125-137, 2000.
4. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, and Mackman N. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor α expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 98: 1429-1439, 2001.
5. Hambleton J, Weinstein SL, Lem L, and DeFranco AL. Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci USA 93: 2774-2778, 1996.
6. Hirose J, Ozawa T, Miura T, Isaji M, Nagao Y, Yamashiro K, Nii A, Kato K, and Uemura A. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 21: 651-656, 1998.
7. Isobe H, Okajima K, Uchiba M, Harada N, and Okabe H. Antithrombin prevents endotoxin-induced hypotension by inhibiting the induction of nitric oxide synthase in rats. Blood 99: 1638-1645, 2002.
8. Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, and Okabe H. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104: 1171-1175, 2001.
9. Jönsson BM, Ohlsson K, and Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chem 370: 1157-1161, 1989.
10. Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, and Waltersdorf AM. Stimulation of neutrophils by tumor necrosis factor. J Immunol 136: 4220-4225, 1986.
11. 1 signaling cascade. J Biol Chem 278: 7790-7799, 2003.
12. Lodie TA, Savedra R, Golenbock DT, Van Beveren CP, Maki RA, and Fenton MJ. Stimulation of macrophage by lipopolysaccharide alters the phosphorylation state, conformation, and function of PU. 1 via activation of casein kinase II. J Immunol 158: 1848-1856, 1997.
13. Nishiyama T, Aibiki M, and Hanaoka K. The effects of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymolphonuclear granulocyte elastase. Anesth Analg 82: 108-112, 1996.
14. Ohnishi H, Kosuzume H, Ashida Y, Kato K, and Honjo I. Effects of urinary trypsin inhibitor on pancreatic enzyme and experimental acute pancreatitis. Dig Dis Sci 29: 26-32, 1984.
15. Okabe H, Irita K, Kurosawa K, Tagawa K, Koga A, Yamakawa M, Yoshitaka J, and Takahashi S. Increase in the plasma concentration of reduced glutathione observed in rats with liver damage induced by lipopolysaccharide/D- galactosamine: effects of ulinastatin, a urinary trypsin inhibitor. Circ Shock 41: 268-272, 1993.
16. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 184: 258-274, 2001.
17. Okajima K, Harada N, and Uchiba M. Microthrombus formation enhances tumor necrosis factor-alpha production in the development of ischemia/reperfusion- induced liver injury in rats. J Thromb Haemost 1: 1316-1317, 2003.
18. Okano S, Tagawa M, Urakawa N, and Ogawa R. A therapeutic effect of ulinastatin on endotoxin-induced shock in dogs-comparison with methylprednisolone. J Vet Med Sci 56: 645-649, 1994.
19. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477, 1993.
20. Rosengart MR, Arbabi S, Garcia I, and Maier RV. Interactions of calcium/calmodulin-dependent protein kinases (CaMK) and extracellular-regulated kinase (ERK) in monocyte adherence and TNF-α production. Shock 13: 183-189, 2000.
21. Sato Y, Ishikawa S, Otaki A, Takahashi T, Hasegawa Y, Suzuki M, Yamagishi T, and Morishita Y. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokines and postoperative organ injury. Jpn J Thorac Cardiovasc Surg 48: 428-434, 2000.
22. Shi L, Kishore R, McMullen MR, and Nagy LE. Lipopolysaccharide stimulation of ERK1/2 increases TNF-α production-via Egr-1. Am J Physiol Cell Physiol 282: C1205-C1211, 2002.
23. Szabo Mitchell JA, Thiemermann C, and Vane JR. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 108: 786-792, 1993.
24. Tani T, Aoki H, Yoshioka T, Lin KJ, and Kodama M. Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomized, controlled trial. Crit Care Med 21: 925-930, 1993.
25. Thiemermann C, Wu CC, Szabo C, Perretti M, and Vane JR. Role of tumor necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol 110: 177-182, 1993.
26. Uchiba M, Okajima K, Murakami K, Okabe H, and Takatsuki K. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Respir Crit Care Med 155: 711-718, 1997.
27. Westlin WF and Gimbrone MA Jr. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol 142: 117-128, 1993.
28. Yamaguchi Y, Ohshiro H, Nagao Y, Odawara K, Okabe K, Hidaka H, Ishihara K, Uchino S, Furuhashi T, Yamada S, Mori K, and Ogawa M. Urinary trypsin inhibitor reduces C-X-C chemokine production in rat liver ischemia/reperfusion. J Surg Res 94: 107-115, 2000.
29. Yang S, Lim YP, Zhou M, Salvemini P, Schwinn H, Josic D, Koo DJ, Chaudry IH, and Wang P. Administration of human inter-alpha-inhibitors maintains hemodynamic stability and improves survival during sepsis. Crit Care Med 30: 617-622, 2002.
30. Yao J, Mackman N, Edgington TS, and Fan ST. Lypopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells: regulation by Egr-1, c-Jun and NF-κB transcription factors. J Biol Chem 272: 17795-17801, 1997.
31. Yuksel M, Okajima K, Uchiba M, and Okabe H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. J Pharmacol Exp Ther 305: 298-305, 2003.